Just weeks after raising a $105 million Series C, Cognito Therapeutics has announced a new Alzheimer’s collaboration with Ochsner Health. The partnership centers on a Brain Health Collaboratory designed to support new care models, build a Brain Health Index, and track disease progression and treatment response in real-world settings. Cognito’s investigational Spectris platform sits at the center of that effort. 

The deal lands within a wider evolution in neurotech partnerships. At one end are the hospital collaborations that underpin implantable research, where surgical access and controlled studies define relationships. Further along are translational partnerships such as last year’s INBRAIN’s Mayo Clinic agreement, which tie clinical evaluation more directly to development and commercialization. Cognito’s Ochsner deal extends that logic into the care-system layer. The partner is not only helping validate the product, but helping shape the framework around how it may ultimately fit into real-world care.

Inside the Partnership

Cognito Therapeutics and Ochsner Health are launching a Brain Health Collaboratory focused on Alzheimer’s. The collaboration is framed around new care models, with plans to develop a Brain Health Index and generate real-world measures of disease progression, cognitive health, and treatment response around Cognito’s investigational Spectris platform. Ochsner is a large nonprofit integrated health system spanning Louisiana, Mississippi, and the Gulf South, with 47 hospitals and more than 370 health and urgent care centers. 

The timing follows directly from Cognito’s oversubscribed $105 million Series C in early March. The company said the round would fund the upcoming pivotal HOPE readout, regulatory preparation, and the operational build-out required for commercialization. Its lead product, Spectris, is an investigational non-invasive visual and auditory stimulation platform for Alzheimer’s disease, with FDA Breakthrough Device Designation.

The product is positioned as a physician-prescribed, at-home therapy and has a planned 2027 U.S. launch, pending FDA review. Cognito recently presented new AD/PD 2026 data, showing links between Spectris-induced brain activity changes and measures of cognition, daily function, and structural brain preservation, alongside new findings on working-memory-related neural responses. 

Ochsner is not the first institutional partnership Cognito closed. In November 2025, Cognito and WVU Rockefeller Neuroscience Institute launched a Brain Health Collaboratory built around AI-powered research and the validation and delivery of non-drug neurotherapies. Ochsner broadens that model, bringing a larger integrated care network and a more explicit link to routine care environments, longitudinal tracking, and regional patient reach. 

Clinical Care Partnerships are Evolving

Clinical partnerships have long been integral to how neurotech moves toward validation and commercialization. In implantable BCI, that usually means working with hospitals and academic medical centers that can provide neurosurgical access, operating-room context, IRB oversight, and carefully selected patient populations. 

In recent times, Precision Neuroscience and Synchron followed that pattern closely. Precision announced collaborations with Mount Sinai, Penn, and later Beth Israel Deaconess, built around studying and mapping brain activity in clinical setting. Synchron has, so far, relied on sites such as Mount Sinai and UPMC to support implantation and formal execution of its COMMAND study.

More recently, partnerships have started to push beyond a research-enabling model. In September 2025, INBRAIN, a Barcelona-based company developing graphene-based BCI, announced an agreement with Mayo Clinics framed around non-exclusive know-how collaboration. 

The partnership is designed to accelerate both technical development and future U.S. commercialization. Mayo experts are set to work with the company on hands-on evaluation of its investigational platform in IRB-approved settings, giving the partnership a more translational profile than traditional arrangements and a clearer role in INBRAIN’s U.S. clinical expansion.

Cognito’s Ochsner deal moves one step further. The collaboration is not centered on a focused validation program or capacity planning. Instead, Ochsner and Cognito are building a regional care network, measures for real-world tracking of disease progression and treatment response, and new care models for Alzheimer’s disease, alongside the generation of clinical and health economics data tied to coverage pathways.

[Image credit: Oschner Health]